TP53 and neoplasm: Interestingly, Panneerdoss et al (2018) revealed that METTL14 knockdown in BRCA cells (MDA‐MB‐431, MDA‐MB‐468, and BT‐549) carrying diverse p53 mutations led to reduced long‐term viability, migration, and invasion of BRCA cells, which, together with clinical data (Fig 6G) revealing a different role for METTL14 in mutant tumors, supports the idea that METTL14 can only employ wild‐type p53‐dependent tumor‐suppressive mechanisms.